Condition
Neoplasms, Hormone-Dependent
Total Trials
4
Recruiting
0
Active
0
Completed
2
Success Rate
50.0%-37% vs avg
Key Insights
Highlights
Success Rate
50% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 80/100
Termination Rate
50.0%
2 terminated out of 4 trials
Success Rate
50.0%
-36.5% vs benchmark
Late-Stage Pipeline
75%
3 trials in Phase 3/4
Results Transparency
0%
0 of 2 completed with results
Key Signals
50% success
Data Visualizations
Phase Distribution
4Total
P 2 (1)
P 3 (3)
Trial Status
Terminated2
Completed2
Trial Success Rate
50.0%
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (4)
Showing 4 of 4 trials
NCT00044291Phase 3Completed
Phase III Study of Atamestane Plus Toremifene Versus Letrozole in Advanced Breast Cancer
NCT00748358Phase 2Completed
An Open-label Phase II Study With SUTENT in Patients Suffering From Hormone Refractory Prostate Cancer
NCT00267553Phase 3Terminated
Treatment and Survival Continuation Study of Atamestane Plus Toremifene vs Letrozole in Advanced Breast Cancer
NCT00097344Phase 3Terminated
The CAT Study: Atamestane Plus Toremifene Versus Letrozole in Advanced Breast Cancer
Showing all 4 trials